29 related articles for article (PubMed ID: 34388457)
1. Full antagonism of the estrogen receptor without a prototypical ligand side chain.
Srinivasan S; Nwachukwu JC; Bruno NE; Dharmarajan V; Goswami D; Kastrati I; Novick S; Nowak J; Cavett V; Zhou HB; Boonmuen N; Zhao Y; Min J; Frasor J; Katzenellenbogen BS; Griffin PR; Katzenellenbogen JA; Nettles KW
Nat Chem Biol; 2017 Jan; 13(1):111-118. PubMed ID: 27870835
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the ESR1 Conformational Stability and Screening Potent Inhibitors for Breast Cancer Treatment.
Sharma K; Panwar U; Madhavi M; Joshi I; Chopra I; Soni L; Khan A; Bhrdwaj A; Parihar AS; Mohan VP; Prajapati L; Sharma R; Agrawal S; Hussain T; Nayarisseri A; Singh SK
Med Chem; 2024; 20(3):352-368. PubMed ID: 37929724
[TBL] [Abstract][Full Text] [Related]
3. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
Kershaw V; Hickey I; Wyld L; Jha S
Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():7-17. PubMed ID: 34416580
[TBL] [Abstract][Full Text] [Related]
4. Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+ primary ductal breast carcinoma: A meta-analysis of microarray datasets.
Albogami SM; Asiri Y; Asiri A; Alnefaie AA; Alnefaie S
Saudi Pharm J; 2021 Jul; 29(7):656-669. PubMed ID: 34400859
[TBL] [Abstract][Full Text] [Related]
5. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Gelmon K; Walshe JM; Mahtani R; Joy AA; Karuturi M; Neven P; Lu DR; Kim S; Schnell P; Bananis E; Schwartzberg L
Breast; 2021 Oct; 59():321-326. PubMed ID: 34388698
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of the prognostic value and immune microenvironment of mitophagy-related signature for multiple myeloma.
Jia Y; Liu R; Shi L; Feng Y; Zhang L; Guo N; He A; Kong G
BMC Cancer; 2023 Sep; 23(1):859. PubMed ID: 37700273
[TBL] [Abstract][Full Text] [Related]
8. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity.
Guo WY; Zeng SM; Deora GS; Li QS; Ruan BF
Curr Top Med Chem; 2019; 19(15):1318-1337. PubMed ID: 31215379
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
10. OBHS impairs the viability of breast cancer via decreasing ERα and Atg13.
Zhou J; Shen R; Zhou HB; Huang J
Biochem Biophys Res Commun; 2021 Oct; 573():69-75. PubMed ID: 34388457
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism.
Wu J; Yan J; Fang P; Zhou HB; Liang K; Huang J
Cancer Lett; 2020 Jan; 469():78-88. PubMed ID: 31629931
[TBL] [Abstract][Full Text] [Related]
12. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
[TBL] [Abstract][Full Text] [Related]
13. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
[TBL] [Abstract][Full Text] [Related]
14. Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
Ning W; Hu Z; Tang C; Yang L; Zhang S; Dong C; Huang J; Zhou HB
J Med Chem; 2018 Sep; 61(18):8155-8173. PubMed ID: 30053783
[TBL] [Abstract][Full Text] [Related]
15. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
